Page last updated: 2024-11-05

benzetimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Benzetimide is a synthetic compound that has been studied for its potential therapeutic applications. It is a potent and selective inhibitor of the enzyme phosphodiesterase 4 (PDE4), which is involved in the regulation of inflammation and other cellular processes. Benzetimide has shown promise in preclinical studies as a potential treatment for inflammatory diseases such as asthma and rheumatoid arthritis. However, its clinical development has been hampered by concerns about its safety profile, particularly its potential to cause hepatotoxicity. The synthesis of benzetimide involves a multi-step process that starts with the reaction of benzoyl chloride with aniline. The resulting amide is then reacted with a suitable alkylating agent to produce the desired compound. The biological effects of benzetimide are primarily mediated through its inhibition of PDE4, which leads to an increase in the levels of cyclic adenosine monophosphate (cAMP) in cells. cAMP is a second messenger molecule that plays a role in a variety of cellular processes, including inflammation, cell proliferation, and apoptosis. The importance of benzetimide lies in its potential to be a valuable therapeutic agent for the treatment of inflammatory diseases. Its selectivity for PDE4 makes it a promising candidate for the development of novel drugs with fewer side effects than current therapies. However, further research is needed to address the safety concerns surrounding benzetimide before it can be considered for clinical use.'

Cross-References

ID SourceID
PubMed CID21847
CHEMBL ID10272
CHEBI ID188883
SCHEMBL ID148330
MeSH IDM0006101

Synonyms (48)

Synonym
EU-0015149
[3,4'-bipiperidine]-2,6-dione, 3-phenyl-1'-(phenylmethyl)-, (s)-
D07513
benzetimide (inn)
spasmental [veterinary] (tn)
119391-55-8
NCGC00160474-01
NCGC00160474-02
benzetimide
dexbenzetimide
L001340
spasmental
CHEMBL10272 ,
AKOS005066173
14051-33-3
3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione
CHEBI:188883
(+/-)-1''-benzyl-3-phenyl-3,4''-bipiperidine-2,6-dione
dexetimide1''-benzyl-3-phenyl-[3,4'']bipiperidinyl-2,6-dione
(+)-1''-benzyl-3-phenyl-3,4''-bipiperidine-2,6-dione
(-)-1''-benzyl-3-phenyl-3,4''-bipiperidine-2,6-dione
bdbm50018556
b987t0l5fx ,
(+-)-benzetimide
(rs)-3-(1-benzyl-4-piperidyl)-3-phenyl-2,6-piperidindion
(3,4'-bipiperidine)-2,6-dione, 3-phenyl-1'-(phenylmethyl)-
benzezimida [inn-spanish]
2-(1-benzyl-4-piperidyl)-2-phenylglutarimide
benzetimide [inn]
benzezimida
benzetimidum
benzetimidum [inn-latin]
unii-b987t0l5fx
dextrobenzetimide
cas-14051-33-3
dtxsid2046173 ,
tox21_111838
dtxcid0026173
benzetimide [mi]
1'-benzyl-3-phenyl-[3,4'-bipiperidine]-2,6-dione
SCHEMBL148330
LQQIVYSCPWCSSD-UHFFFAOYSA-N
(+/-)-benzetimide
[3,4'-bipiperidine]-2,6-dione,3-phenyl-1'-(phenylmethyl)-
EX-A3066
Q27274534
()-benzetimide
3-(1-benzyl-4-piperidyl)-3-phenyl-piperidine-2,6-dione

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency14.12540.01237.983543.2770AID1346984
pregnane X nuclear receptorHomo sapiens (human)Potency5.62340.005428.02631,258.9301AID1346985
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.89130.035520.977089.1251AID504332
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)5.00050.00001.23267.7930AID348585
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)5.00050.00001.403910.0000AID348584
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)5.00050.00011.01049.9280AID348586
C-X-C chemokine receptor type 3Homo sapiens (human)IC50 (µMol)10.00000.00500.35886.5600AID348583
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
angiogenesisC-X-C chemokine receptor type 3Homo sapiens (human)
regulation of leukocyte migrationC-X-C chemokine receptor type 3Homo sapiens (human)
apoptotic processC-X-C chemokine receptor type 3Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 3Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 3Homo sapiens (human)
cell adhesionC-X-C chemokine receptor type 3Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 3Homo sapiens (human)
regulation of cell adhesionC-X-C chemokine receptor type 3Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 3Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 3Homo sapiens (human)
immune responseC-X-C chemokine receptor type 3Homo sapiens (human)
cell chemotaxisC-X-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 3Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
chemokine bindingC-X-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 3Homo sapiens (human)
cytoplasmC-X-C chemokine receptor type 3Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 3Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID348586Binding affinity to human muscarinic M3 receptor2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.
AID348585Binding affinity to human muscarinic M2 receptor2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.
AID348584Binding affinity to human muscarinic M1 receptor2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.
AID78477Ability to bind to guinea pig atrial homogenate1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Accumulation of drugs by guinea pig isolated atria. Quantitative correlations.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID23672Partition coefficient (logP)1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Accumulation of drugs by guinea pig isolated atria. Quantitative correlations.
AID142487Displacement of [3H]N-methylscopolamine from rat brain homogenate1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist.
AID348583Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ITAC challenge2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.
AID91479Ability to bind to human serum albumin1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Accumulation of drugs by guinea pig isolated atria. Quantitative correlations.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (33.33)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's2 (22.22)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.37 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index37.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]